GSK PLC
[WKN: A3DMB5 | ISIN: GB00BN7SWP63]
Aktienkurse
16,280€ 1,94%
Echtzeit-Aktienkurs GSK PLC
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

GSK Aktie: Story nicht wesentlich verändert

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…

GSK Aktie: Das ist ein Paukenschlag!

Kulmbach (www.aktiencheck.de) - GSK-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

GSK: Does RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

GSK cancer drugs fast-tracked by Chinese

GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has…

GSK sees positive COPD trial results

GSK PLC (LSE:GSK, NYSE:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive...…

GSK wins Illinois court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK wins Illinois Zantac court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK: Impfstoffsegment enttäuscht - Aktienanalyse

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…